No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
THAR Tharimmune
- 2.965
- -0.115-3.73%
Close Jun 18 16:00 ET
- 2.890
- -0.075-2.53%
Post 19:23 ET
2.33MMarket Cap-132P/E (TTM)
3.150High2.920Low41.45KVolume2.950Open3.080Pre Close125.93KTurnover5.37%Turnover RatioLossP/E (Static)786.03KShares163.08852wk High0.33P/B2.29MFloat Cap2.75052wk Low--Dividend TTM771.80KShs Float1590.000Historical High--Div YieldTTM7.47%Amplitude2.750Historical Low3.037Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Tharimmune Reports Type C Meeting With FDA For Phase 2 Program For TH104
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersScinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 77.4% to $6.19 during Monday's pre-market session. The company's market cap stands at $3.5 million. ENDRA Life Sciences (NASDAQ:ND
Express News | Tharimmune Receives Notice From Nasdaq Confirming Compliance With Minimum Bid Price Requirement
Express News | Tharimmune : Received Notice From Nasdaq That Co Has Regained Compliance With Minimum Bid Price Requirement
Tonix TNXP Reverse Stock Split 1-for-32; Tharimmune THAR Offering
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) fell sharply during Monday's session after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and
Comments
$Tharimmune(THAR.US$ looks like a fraud organisation.
$Tharimmune(THAR.US$
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Tharimmune has received positive feedback from the FDA for its Phase 2 clinical trial of TH104, a transmucosal buccal film containing nalmefene, for treating moderate-to-severe pruritus in primary biliary cholangitis (PBC). This feedback supports Tharimmune's plan to pursue a 505(b)(2) approval pathway, al...
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Tharimmune has received positive feedback from the FDA for its Phase 2 clinical trial of TH104, a transmucosal buccal film containing nalmefene, for treating moderate-to-severe pruritus in primary biliary cholangitis (PBC). This feedback supports Tharimmune's plan to pursue a 505(b)(2) approval pathway, al...
1
$Tharimmune(THAR.US$ Received Notice From Nasdaq That Co Has Regained Compliance With Minimum Bid Price Requirement
1
5
$Tharimmune(THAR.US$
Sold for now with loss. Not looking good to hold for long time. Pullback phase was on already
Sold for now with loss. Not looking good to hold for long time. Pullback phase was on already
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg